Registry Experience at the Washington Hospital Center, DES - Xience V
This trial is active, not recruiting.
|Condition||coronary artery disease|
|Sponsor||Medstar Research Institute|
|Start date||August 2009|
|End date||September 2011|
|Trial size||1000 participants|
|Trial identifier||NCT01003977, REWARDS XV|
Single center registry of patients who have received a Xience V everolimus-eluting stent at the Washington Hospital Center, with the primary objective to assess clinical success and safety at 30 days, 6 months and 1 year post-implantation.
Patients treated with a Xience V everolimus-eluting stent
Evaluation of Major Adverse Cardiac Events (MACE) post Xience V implantation
time frame: Follow Up
Male or female participants at least 18 years old.
- Patients, male or female, >18 years of age
- Patients who received at least one Xience V drug-eluting stent at the Washington Hospital Center
- Patients who received another type of DES (other than Xience V) or a bare metal stent at the time of initial Xience V stent implantation
|Official title||REWARDS (Registry Experience at the Washington Hospital Center, DES - Xience V)|
|Principal investigator||Ron Waksman, MD|
|Description||Interventional cardiology was revolutionized by the invention of stents, initially with the bare-metal stents (BMS) and recently with the drug-eluting stents (DES). The everolimus eluting, Xience V stents have shown very promising results in randomized clinical trials, demonstrating a reduction of clinical and angiographic restenosis in comparison to BMS, and comparable clinically-driven target lesion revascularization rates in comparison with sirolimus-eluting stents. While registry data is available from outside of the United States, it will be important to collect "real-world" data regarding the stent usage and outcomes in the United States. In this study we propose to follow patients who received at least one Xience V® Stent for at least 1 year post initial stent implantation.|
Call for more information